LC/MS/MS法测定人血浆中头孢克肟含量

目的 建立人血浆中头孢克肟的LC/MS/MS法.方法 血浆样品经蛋白沉淀提取,采用C8色谱柱分析,以乙腈:水:甲酸(40:60:0.5,v/v/v)为流动相,三重四级杆质谱检测器,正离子多反应监测模式(MRM),监测离子分别为:m/z 454.3→m/z 285.2(头孢克肟),m/z 282.2→m/z 212.2(...     

液相色谱-串联质谱法测定人血浆中氟氯西林的含量

目的为临床制定安全有效的给药方案提供参考。方法采用液相色谱-串联质谱(LC-MS-MS)法。血浆样品经液-液萃取处理后,以乙腈-水(体积比25∶75)为流动相,采用Zorbax Ec lipseXDB C8柱(150 mm×4.6 mm,5μm)分离;通过电喷雾三重四级杆串联质谱,以负离子、选择反应监测方式进行检测,用于定量的离子反应分别为m/z452→m/z311(氟氯西林)和m/z468→m/z327(内标双氯西林)。结果氟氯西林线性范围为20.0~15000μg.L-1,定量下限为20.0μg.L-1,提取回收率均大于70%,日内、日间精密度均小于7%。结论该法适用于注射用氟氯西林钠的单次肌内注射给药的药物动力学研究。     

Quantitative determination of sufentanil in human plasma by liquid chromatography-tandem mass spectrometry

A sensitive and specific method for the quantification of sufentanil in human plasma by liquid chromatography coupled with tandem mass spectrometry has been developed. Fentanyl was used as the internal standard. Rapid sample preparation involved purification on a C(18) solid-phase extraction column. Chromatographic separation of the analytes was obtained using an RP-C(18) mu-HPLC column. LC-MS-MS detection was performed by atmospheric pressure ionisation (API) source equipped with an ionspray (IS) interface operating in the positive ion mode. For unambiguous substance confirmation, three analyte precursor-product ion combinations were monitored during multiple reaction monitoring (MRM) LC-MS-MS analysis. The method's performance characteristics were evaluated in blank and spiked control plasma samples. Overall accuracy (relative error, R.E., %), repeatability (relative standard deviations, R.S.D., %) and within-laboratory reproducibility (R.S.D., %) ranged from -9.28 to -2.71%, from 6.42 to 2.82% and from 13.52 to 6.06%, respectively, for sufentanil. The limit of quantification for sufentanil in human plasma samples was 0.3 ng ml(-1). Due to its high sensitivity and specificity, the method was successfully employed for sufentanil determination in maternal plasma samples collected immediately before epidural administration of a single sufentanil dose to women in labour, 20 min after drug administration, and at birth in arterial and venous umbilical cord plasma samples from the newborn babies. Research is in progress to adopt the method for performance of complete pharmacokinetic studies of sufentanil in human plasma.     

Determination of tiapride in human plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry

A rapid, sensitive and selective hydrophilic interaction liquid chromatography-tandem mass spectrometric (HILIC-MS/MS) method for the determination of tiapride in human plasma was developed. Tiapride and internal standard, metoclopramide were extracted from human plasma with dichloromethane at basic pH and analyzed on an Atlantis HILIC silica column with the mobile phase of acetonitrile-ammonium formate (190 mM, pH 3.0) (94:6, v/v). The analytes were detected using an electrospray ionization tandem mass spectrometry in the multiple-reaction-monitoring mode. The standard curve was linear (r=0.999) over the concentration range of 1.00-200 ng/mL. The coefficient of variation and relative error for intra- and interassay at three QC levels were 6.4-8.8% and -2.0-3.6%, respectively. The recoveries of tiapride ranged from 96.3 to 97.4%, with that of metoclopramide (internal standard) being 94.2%. The lower limit of quantification for tiapride was 1.00 ng/mL using 100 microL of plasma sample.     

New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma

With the objective of reducing analysis time and maintaining good efficiency, there has been substantial focus on high-speed chromatographic separations and ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) is a preeminent analytical tool for rapid biomedical analysis. In this study a simple, rapid, sensitive, and specific ultra-performance liquid chromatography-MS/MS method was developed and validated for quantification of the angiotensin II receptor antagonist, irbesartan (IRB), in human plasma. After a simple protein precipitation using methanol and acetonitrile, IRB and internal standard (IS) telmisartan were separated on Acquity UPLC BEH C18 column (50 mm × 2.1 mm, i.d. 1.7 μm, Waters, Milford, MA, USA) using a mobile phase consisted of acetonitrile: methanol: 10 mM ammonium acetate (70: 15: 15 v/v/v) with a flow rate of 0.4 mL/min and detected MS/MS in negative ion mode. The ion transitions recorded in multiple reaction monitoring mode were m/z 427.2→193.08 for IRB and m/z 513.2→469.3 for IS. The assay exhibited a linear dynamic range of 2–500 ng/mL for IRB in human plasma with good correlation coefficient of (0.995) and with a lower limit of quantitation of 2 ng/mL. The intra- and interassay precisions were satisfactory; the relative standard deviations did not exceed 9.91%. The proposed UPLC-MS/MS method is simple, rapid, and highly sensitive, and hence it could be reliable for pharmacokinetic and toxicokinetic study in both animals and humans.     

液相色谱-串联质谱法同时测定人血浆中伪麻黄碱和苯海拉明

伪麻黄碱 (ｐｓｅｕｄｏｅｐｈｅｄｒｉｎｅ)为拟交感神经类药物 ,临床常用于治疗感冒、支气管炎等上呼吸道感染疾病。苯海拉明 (ｄｉｐｈｅｎｈｙｄｒａｍｉｎｅ)为Ｈ1 受体拮抗剂 ,具抗组胺活性 ,同时还具镇静、止呕和抗副交感神经生理作用等特点。临床上常将二者复方用药 ,既能发挥伪麻黄碱消除上呼吸道粘膜充血的功能 ,又可利用苯海拉明促进睡眠、有助于机体自身免疫系统发挥作用等特点。有文献报道单独测定人血浆中的伪麻黄碱[1～ 4]或苯海拉明的方法[5～ 7] ,但这些方法均有一定局限性 ,无法满足同时测定两种成分的需要。本文旨在建立…     

HPLC-MS-MS法定量测定人血浆中多潘立酮的浓度

目的：建立HPLC-MS-MS方法定量测定人血浆中多潘立酮浓度。方法：以地西泮为内标,采用甲醇：0.5%乙酸=80：20为流动相,以Inerstil C18（2.1mm×100mm,3.0μm）色谱柱为分析柱,通过电喷雾离子源（ESI）,以正离子多反应监测（MRM）方式进行检测。多潘立酮和地西泮用于定量分析的离子对分别为[M＋H]^＋m/z426.2→m/z175.2和[M＋H]^＋m/z285.0→m/z193.0。结果：多潘立酮线性范围为1～80μg·L-1,定量下限为1μg·^L-1（n=6）。日内、日间的RSD均〈15%,平均回收率〉75%。结论：本方法专属性强,样品处理方便,灵敏度高,适用于多潘立酮临床药动学研究。     

超高效液相色谱串联质谱法快速测定尼扎替丁在人体血浆中的含量

目的: 建立超高效液相色谱串联质谱法测定人体血浆中尼扎替丁的含量。方法: 血浆以甲醇直接沉淀蛋白, 上清液用于目标物的检测;色谱柱为Waters ACQUITY UPLC BEH C₁₈;流动相为5 mmol·L^-1醋酸铵水溶液-甲醇 (65:35, V/V);流速:0.20 mL·min^-1;进样量:3 μL;柱温:35 ℃;样品室温度:6 ℃;采用电喷雾正离子模式电离, 尼扎替丁和内标雷尼替丁的监测离子分别为(m/z)332.2→155.0, (m/z)315.2→130.0。结果: 尼扎替丁的线性范围为10~3 000 ng·mL^-1, 平均回收率为93.2%~101.1%, 批内、批间RSD均小于15%。结论: 本研究建立的分析方法快速、准确、灵敏、简便, 适用于尼扎替丁人体药动学方面的研究。     

HPLC-MS/MS法测定人体血浆中吲哒帕胺的浓度

目的:建立一种简便、灵敏的测定人体血浆中吲哒帕胺浓度的高效液相色谱-串联质谱(HPLC-MS/MS)方法。方法:以瑞格列奈钙为内标,采用乙腈:0.1%甲酸水溶液=90∶10为流动相,以Agilent-ZORBAX-C18柱(2.1mm×150mm,5.0m)色谱柱为分析柱,通过电喷雾离子源(ESI),以正离子多反应监测(MRM)方式进行进样检测。检测离子为[M+H]+m/z 364.1m/z 188.8(吲哒帕胺)和[M+H]+m/z 451.1m/z 134.8(瑞格列奈钙,内标)。结果:吲哒帕胺线性范围为0.5～50ng/mL,定量下限为0.5ng/mL,线性关系良好;高、中、低三个浓度的日内、日间的RSD均<15%,平均回收率为94.60%～110.33%。结论:本方法专属性强,操作简便,灵敏度高,适用于吲哒帕胺制剂的临床药动学研究。     

HPLC-MS/MS法测定人血浆中雷喏嗪的质量浓度

目的建立HPLC-MS/MS法测定人血浆中雷喏嗪的质量浓度。方法以伏立康唑为内标,采用乙腈-体积分数0.1%甲酸水溶液(90∶10)为流动相,以Agilent-ZORBAX-C18柱(150 mm×2.1 mm,5.0μm)色谱柱为分析柱,通过电喷雾离子源(ESI),以正离子多反应监测(MRM)方式进行检测。雷喏嗪和伏立康唑用于定量分析的离子对分别为[M+H]+m/z428.5→m/z279.3和[M+H]+m/z350.2→m/z281.3。结果雷喏嗪线性范围为20~5 000 ng·mL-1,定量下限为20 ng·mL-1。日内和日间的RSD均小于15%,平均回收率大于75%。结论该方法专属性强,样品处理方便,灵敏度高,适用于雷喏嗪的临床药动学研究。     

液相色谱-串联质谱法同时测定人血浆中二甲双胍和格列吡嗪

建立了快速、灵敏的液相色谱-串联质谱法测定人血浆中的二甲双胍和格列吡嗪。血浆样品经0.3%甲酸-乙腈(v/v)沉淀蛋白后，以乙腈-水-甲酸(70∶30∶0.3，v/v/v)为流动相，流速为0.50 mL·min^-1。Zorbax Extend C₁₈柱分离，采用大气压化学电离源；以选择反应监测(SRM)方式进行正离子检测。用于定量分析的离子反应分别为m/z 130→m/z 60(二甲双胍)，m/z 446→m/z 321(格列吡嗪)和m/z 256→m/z 167(内标，苯海拉明)。测定血浆中二甲双胍的线性范围为2.00～2 000 ng·mL^-1， 定量下限为2.00 ng·mL^-1； 格列吡嗪的线性范围为1.00～1 000 ng·mL^-1， 定量下限为1.00 ng·mL^-1。该方法专属性好，灵敏度高，准确快捷，适用于二甲双胍和格列吡嗪的临床药代动力学研究。     

液相色谱-串联质谱法同时测定人血浆中西替利嗪和伪麻黄碱的浓度

目的建立同时测定人血浆中西替利嗪和伪麻黄碱血药浓度的液相色谱-串联质谱(LC-MS/MS)定量方法。方法以甲磺酸罗哌卡因为内标,血浆样品经蛋白沉淀处理后,在0.2 mL.min-1的流速下梯度洗脱,采用CAPCELL PAK C18柱(50 mm×2.0 mm,5μm)分离。样品经电喷雾离子源(ESI)正离子化后,通过三级四极杆串联质谱仪,采用多反应离子检测方式测定西替利嗪(m/z389.2/201.1)、伪麻黄碱(m/z166.2/148.1)和内标甲磺酸罗哌卡因(m/z275.3/126.1)的浓度。结果西替利嗪和伪麻黄碱分别在2.5~1 000和5~2 000μg.L-1质量浓度范围内线性良好,最低检测浓度分别为2.5和5μg.L-1。方法的相对回收率在85%~115%之间,批内、批间RSD均<15%。结论本方法专属性强、灵敏度高,操作简便、快速,符合生物样品分析要求,适用于临床药动学研究。     

Liquid chromatography-tandem mass spectrometry method for the determination of trimetazidine in human plasma

A sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS) method was developed and validated for the determination of trimetazidine (CAS 13171-25-0) in human plasma, using pseudoephedrine as internal standard (IS). Plasma samples were simply pretreated with methanol for deproteinization. The chromatographic separation was performed on a C18 column with a mobile phase of 3 mmol/L ammonium acetate solution-methanol (15:85, v/v) at a flow rate of 0.3 mL/min. The chromatographic separation was achieved in less than 3.2 min. The linearity was established over the concentration range of 1-100 ng/mL. Both intra- and inter-batch standard deviations were less than 9.5%. The method was successfully applied to study the relative bioavailability of trimetazidine hydrochloride tablets in healthy Chinese volunteers and the pharmacokinetic parameters of the reference and test tablets were compared.     

高效液相色谱-串联质谱法测定人血浆中色氨酸及其代谢物浓度

目的建立一种基于高效液相色谱-串联质谱(LC-MS/MS)技术同时快速测定人血浆中色氨酸及其代谢产物(犬尿氨酸、犬尿喹啉酸和吲哚丙酸)含量的方法。方法采用甲醇/乙腈(v/v,50/50)沉淀蛋白,以色氨酸-d_5为内标,色谱柱:Ultimate XB-C_(18) HPLC柱(2.1 mm×100 mm,3μm),流动相:水-甲醇(45/55,水相含5 mmol/L醋酸铵和0.2%甲酸),流速:0.3 ml/min,柱温:40℃,分析时间共3 min。质谱采用API4000 QTrap三重四极杆质谱仪的正离子多反应监测模式监测。考察该方法的专属性、线性及定量范围、精密度与准确度、回收率与基质效应以及稳定性。结果色氨酸、犬尿氨酸、犬尿喹啉酸及吲哚丙酸的线性范围分别在100～2×10~4、25～5 000、5～1 000、10～2 000 ng/ml;平均回收率均>90%;日内和日间精密度(RSD)和准确度(RE)均小于15%;稳定性良好。该方法成功测定了90例冠心病患者血浆中的色氨酸、犬尿氨酸、犬尿喹啉酸及吲哚丙酸的浓度。结论该方法简便、快捷、灵敏,可用于人体血浆中色氨酸及其代谢产物浓度的测定。     

LC-MS/MS法测定人体血浆中谷氨酰胺的含量

目的建立测定人血浆中谷氨酰胺浓度的液相色谱串联质谱法(LC-MS/MS)。方法血浆样品用质量分数为10%的三氯乙酸沉蛋白,色谱柱:Inertsil-CN柱,流动相:5 mmol·L~(-1)醋酸铵(含体积分数为0.1%的甲酸)-甲醇-乙腈(体积比为70∶15∶15),流速:750μL·min~(-1),质谱:采用多反应检测模式,API2000电喷雾离子源。结果谷氨酰胺的线性为12~384 mg·L~(-1),定量下限为12 mg·L-1,日间日内精密度(relative standard deviation,RSD)均不大于15%。健康男性受试者单剂量口服谷氨酰胺颗粒5 g后的主要药动学参数为:tmax为(0.77±0.13)h,ρmax为(75.3±29.0)mg·L~(-1),t_(1/2)为(1.83±1.93)h,采用梯形法计算,AUC_(0-t)为(109.2±40.1)mg·h·L~(-1),AUC_(0-∞)为(114.0±40.4)mg·h·L~(-1)。结论该法适合于谷氨酰胺颗粒的人体药动学研究。     

液质联用法测定人血浆中米格列奈的浓度

目的建立LC-MS/MS法测定人血浆中米格列奈的浓度,并研究其在健康男性受试者体内的药动学。方法血浆经液-液萃取。色谱柱:Agilent TC-C18柱,流动相:乙腈-水-甲酸(体积比为70.0∶30.0∶0.3),质谱检测采用多反应监测模式(multiple reaction monitoring,MRM),电喷雾离子源,分析时间:2.0 min。结果米格列奈线性为5.0～4 000.0μg.L-1,定量下限为5.0μg.L-1。日内、日间精密度(relative standard deviation,RSD)均不大于10.5%,准确度(relative error,RE)为-0.8%～-2.0%。健康男性受试者口服含米格列奈10 mg的受试制剂(规格:10 mg/片)和参比制剂(规格:5 mg/片)后主要药动学参数为:tmax分别为(0.375±0.079)和(0.396±0.166)h,ρmax分别为(887±292)和(902±298)μg.L-1,t1/2分别为(1.37±0.45)和(1.49±0.57)h,AUC0-t分别为(1047±379)和(1 067±430)μg.h.L-1,AUC0-∞分别为(1 070±394)和(1 092±433)μg.h.L-1。结论该法适用于米格列奈的药动学及生物等效性研究。     

HPLC-MS-MS法测定人血浆中托吡酯的浓度

目的:建立测定人血浆中托吡酯浓度的HPLC-MS-MS方法。方法:采用液液萃取法,以甲基叔丁基醚为提取溶剂;HPLC采用Hypersil ODS C18色谱柱(150 mm×4.6 mm,5μm),流动相为5 mmol·L-1醋酸铵溶液-甲醇(25∶75),流速0.5 mL·min-1;质谱采用ESI源,负离子检测模式,定量分析离子为托吡酯m/z338.1[M-H]-→78.0,双氯芬酸钠m/z294.1[M-H]-→249.7。结果:人血浆中托吡酯的标准曲线范围为10.00~3 600.00 ng.mL-1(n=7),r>0.999;日内和日间精密度均小于8.9%;提取回收率(低、中、高)分别为(75.5±3.1)%,(77.0±1.6)%和(72.8±1.5)%,内标提取回收率为(76.1±3.5)%;基质效应(低、中、高)分别为(99.2±5.6)%,(98.9±4.2)%和(99.4±3.8)%,内标基质效应为(100.4±1.3)%。结论:该方法灵敏、快速、专属性强,可用于人血浆中托吡酯浓度的测定。     

液质联用法测定人血浆中沙格雷酯的浓度

目的建立人血浆中沙格雷酯质量浓度的液相色谱-串联质谱(LC-MS/MS)测定方法。方法色谱柱为Elipse XDB-C18柱,流动相为乙腈-0.01 mol·L-1醋酸铵(体积比为65∶35),血浆样品经乙腈沉淀蛋白处理,以选择反应监测(selected reaction monitoring,SRM)扫描方式检测,测定健康男性受试者经口给予盐酸沙格雷酯后血浆中沙格雷酯的质量浓度。结果沙格雷酯线性为5.0¹ 000μg·L-1,定量下限为5.0μg·L-1。日内、日间精密度(Relative Standard Deviation,RSD)均不大于9.0%,准确度(Relative Error,RE)为-6.5%1 000μg·L-1,定量下限为5.0μg·L-1。日内、日间精密度(Relative Standard Deviation,RSD)均不大于9.0%,准确度(Relative Error,RE)为-6.5%².6%。沙格雷酯在健康男性血浆中主要药动学参数tmax为(0.49±0.21)h,ρmax为(725±264)μg·L-1,t1/2为(0.58±0.21)h,AUC0-t为(534±111)μg·h·L-1,AUC0-∞为(540±111)μg·h·L-1。结论该方法适用于沙格雷酯在健康人体内药动学的研究。     

液相色谱-串联质谱法测定人血浆中的伪麻黄碱浓度

建立了测定人血浆中伪麻黄碱浓度的液相色谱 串联质谱法。血浆样品经液 液萃取处理后 ,以甲醇 水 甲酸 (体积比 6 0∶40∶2 )为流动相 ,采用ZorbaxC18柱分离 ,通过电喷雾四极杆串联质谱 ,正离子方式检测 ;采用SRM转化m/z 16 6→ 147(伪麻黄碱 )和m/z 2 75→ 12 5 (内标罗哌卡因 )进行定量分析。线性范围为 5 0～ 2 5 0 0ng/mL ,定量限为 5 0ng/mL。应用本法测试了 2 0名健康受试者口服 6 0mg盐酸伪麻黄碱后不同时刻的血浆药物浓度     

液相色谱-串联质谱法测定人血浆中罗格列酮

目的:建立测定人血浆中罗格列酮的液相色谱-质谱-质谱联用法,并用于临床药动学研究。方法: 血浆样品经液-液萃取后,以乙腈-水-甲酸(90:10:0．5)为流动相,采用Zorbax SB—C18柱分离,通过电喷雾离子化四极杆串联质谱,以选择反应监测(SRM)方式进行检测。用于定量分析的离子反应分别为m／z 358→ 135(罗格列酮)和m／z 256→167(内标苯海拉明)。结果:标准曲线线性范围为0．50～1 000μg·L-1,定量下限为0．50μg·L-1,日内、日间精密度(RSD)均小于7．4％。应用此法测试了20名男性健康受试者口服酒石酸罗格列酮片(相当于罗格列酮4 mg)后血浆中罗格列酮的浓度。结论:该法灵敏、快速、准确,操作简便、线性范围宽,适用于罗格列酮的临床药动学研究。